131 related articles for article (PubMed ID: 33610444)
1. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?
Grant Owens R; Loloi J; Lehman EB; Kaag MG; Raman JD; Merrill SB
Urol Oncol; 2021 Jul; 39(7):433.e9-433.e15. PubMed ID: 33610444
[TBL] [Abstract][Full Text] [Related]
2. Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications.
Diamand R; Ploussard G; Roumiguié M; Malavaud B; Oderda M; Gontero P; Fourcade A; Fournier G; Benamran D; Iselin C; Fiard G; Descotes JL; Peltier A; Simone G; Roche JB; Roumeguère T; Albisinni S
Urol Oncol; 2021 May; 39(5):296.e1-296.e9. PubMed ID: 33041188
[TBL] [Abstract][Full Text] [Related]
3. Calibrated Regression Models Based on the Risk of Clinical Nodal Metastasis Should be Used as Decision Aids for Prostate Cancer Staging to Reduce Unnecessary Imaging.
Hayes M; Yu Y; Bassale S; Chakiryan N; Chen Y; Ye S; Garzotto M; Kopp R
Clin Genitourin Cancer; 2022 Dec; 20(6):e490-e497. PubMed ID: 35649886
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis.
Vargas HA; Schor-Bardach R; Long N; Kirzner AN; Cunningham JD; Goldman DA; Moskowitz CS; Sosa RE; Sala E; Panicek DM; Hricak H
Abdom Radiol (NY); 2017 Jan; 42(1):271-277. PubMed ID: 27480976
[TBL] [Abstract][Full Text] [Related]
7. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
[TBL] [Abstract][Full Text] [Related]
8. Application of bone scans for prostate cancer staging: Which guideline shows better result?
Chong A; Hwang I; Ha JM; Yu SH; Hwang EC; Yu HS; Kim SO; Jung SI; Kang TW; Kwon DD; Park K
Can Urol Assoc J; 2014 Jul; 8(7-8):E515-9. PubMed ID: 25210554
[TBL] [Abstract][Full Text] [Related]
9. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT.
Borley N; Fabrin K; Sriprasad S; Mondaini N; Thompson P; Muir G; Poulsen J
Scand J Urol Nephrol; 2003; 37(5):382-6. PubMed ID: 14594685
[TBL] [Abstract][Full Text] [Related]
10. Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients.
Ma MW; Gao XS; Lyu F; Gu XB; Yin H; Li HZ; Li XY; Qi X; Bai Y; Chen JY
World J Urol; 2021 Jun; 39(6):1815-1823. PubMed ID: 32691147
[TBL] [Abstract][Full Text] [Related]
11.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
12. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
13. Guideline-discordant use of imaging during work-up of newly diagnosed prostate cancer.
Falchook AD; Hendrix LH; Chen RC
J Oncol Pract; 2015 Mar; 11(2):e239-46. PubMed ID: 25670199
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors and recommendations for staging computed tomography scan among men with prostate cancer.
Risko R; Merdan S; Womble PR; Barnett C; Ye Z; Linsell SM; Montie JE; Miller DC; Denton BT
Urology; 2014 Dec; 84(6):1329-34. PubMed ID: 25288575
[TBL] [Abstract][Full Text] [Related]
15. Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning.
Falagario UG; Jambor I; Ratnani P; Martini A; Treacy PJ; Wajswol E; Lantz A; Papastefanou G; Weil R; Phillip D; Lewis S; Haines K; Cormio L; Carrieri G; Kyprianou N; Wiklund P; Tewari AK
Minerva Urol Nefrol; 2020 Dec; 72(6):746-754. PubMed ID: 32182231
[TBL] [Abstract][Full Text] [Related]
16. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer.
Pinaquy JB; De Clermont-Galleran H; Pasticier G; Rigou G; Alberti N; Hindie E; Mokrane Y; Fernandez P
Prostate; 2015 Feb; 75(3):323-31. PubMed ID: 25393215
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines.
Stewart SB; Thompson RH; Psutka SP; Cheville JC; Lohse CM; Boorjian SA; Leibovich BC
J Clin Oncol; 2014 Dec; 32(36):4059-65. PubMed ID: 25403213
[TBL] [Abstract][Full Text] [Related]
19. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
20. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
